3 Growth Companies Insiders Are Eager To Own

As global markets continue to navigate geopolitical tensions and economic uncertainties, major U.S. stock indexes have shown resilience, with broad-based gains pushing them toward record highs. Amid this backdrop of cautious optimism, growth companies with high insider ownership stand out as potentially attractive opportunities for investors seeking alignment between company leadership and shareholder interests.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
SKS Technologies Group (ASX:SKS)	32.4%	24.8%
Propel Holdings (TSX:PRL)	36.9%	37.6%
On Holding (NYSE:ONON)	19.1%	29.6%
Pharma Mar (BME:PHM)	11.8%	56.9%
CD Projekt (WSE:CDR)	29.7%	29.6%
Elliptic Laboratories (OB:ELABS)	26.8%	103.6%
EHang Holdings (NasdaqGM:EH)	32.8%	81.5%
Alkami Technology (NasdaqGS:ALKT)	11%	98.6%
Credo Technology Group Holding (NasdaqGS:CRDO)	13.7%	95%
Brightstar Resources (ASX:BTR)	16.2%	84.6%

Click here to see the full list of 1508 stocks from our Fast Growing Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Gan & Lee Pharmaceuticals (SHSE:603087)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China, with a market cap of CN¥27.17 billion.

Operations: The company's revenue primarily comes from the development, production, and sales of insulin and related products, amounting to CN¥2.95 billion.

Insider Ownership: 36.6%

Earnings Growth Forecast: 43.2% p.a.

Gan & Lee Pharmaceuticals demonstrates potential as a growth company with high insider ownership. The company's revenue and earnings are forecast to grow significantly, outpacing the Chinese market. Recent positive clinical trial results for its GLP-1 receptor agonist, GZR18, bolster its innovative pipeline. Strong financial performance is evident with nine-month sales reaching CNY 2.25 billion and net income of CNY 507.27 million, reflecting robust operational execution and strategic focus on long-term growth opportunities.

• Navigate through the intricacies of Gan & Lee Pharmaceuticals with our comprehensive analyst estimates report here.
• The analysis detailed in our Gan & Lee Pharmaceuticals valuation report hints at an inflated share price compared to its estimated value.

Hoshine Silicon Industry (SHSE:603260)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Hoshine Silicon Industry Co., Ltd. produces and sells silicon-based materials both in China and internationally, with a market cap of CN¥68.32 billion.

Operations: Hoshine Silicon Industry Co., Ltd.'s revenue primarily comes from the production and sale of silicon-based materials.

Insider Ownership: 32.6%

Earnings Growth Forecast: 36.5% p.a.

Hoshine Silicon Industry's earnings are projected to grow significantly, outpacing the Chinese market, although revenue growth is expected to be slower. The company's financial health shows challenges with debt coverage and declining profit margins, from 11% last year to 7% now. Recent earnings reported a net income drop from CNY 2.18 billion to CNY 1.45 billion over nine months despite increased sales of CNY 20.37 billion. A share buyback program indicates strategic capital management efforts.

• Take a closer look at Hoshine Silicon Industry's potential here in our earnings growth report.
• Our valuation report here indicates Hoshine Silicon Industry may be overvalued.

Changsha Jingjia Microelectronics (SZSE:300474)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Changsha Jingjia Microelectronics Co., Ltd. operates in the semiconductor industry, focusing on the design and manufacturing of microelectronic products, with a market cap of CN¥43.83 billion.

Operations: The company's revenue primarily comes from the Computer, Communications and Other Electronic Equipment Manufacturing segment, totaling CN¥893.84 million.

Insider Ownership: 34%

Earnings Growth Forecast: 33.4% p.a.

Changsha Jingjia Microelectronics is expected to see significant earnings growth of 33.36% annually, surpassing the Chinese market average. However, recent financials show a decline in revenue from CNY 469.17 million to CNY 441.06 million over nine months, with profit margins also decreasing from 21.4% to 14.7%. The company recently completed a substantial private placement raising approximately CNY 3.83 billion, indicating strategic capital infusion despite past shareholder dilution concerns and share price volatility.

• Click here to discover the nuances of Changsha Jingjia Microelectronics with our detailed analytical future growth report.
• Our expertly prepared valuation report Changsha Jingjia Microelectronics implies its share price may be too high.

Make It Happen

• Gain an insight into the universe of 1508 Fast Growing Companies With High Insider Ownership by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com